<DOC>
	<DOCNO>NCT00527865</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , systemic exposure experimental influenza ( flu ) treatment medication call DAS181 . DAS181 dry powder administer via oral inhalation use special device . Study participant include 60 healthy , non-smoking male female , age 18-65 . They give either DAS181 placebo . Participants remain clinic overnight watch health change 24 hour receive medication . Study procedures include : physical exam , chest x-ray , ECGs , lung function test , collection blood urine sample , throat swab . Follow-up visit occur study day 2 , 7 , 14 +/- 1 day , 30 +/- 2 day . Participants involve study 61 day , include screening period .</brief_summary>
	<brief_title>Single Dose Escalating Study DAS181 Adults</brief_title>
	<detailed_description>The objective study investigate safety , tolerability pharmacokinetics single dose DAS181 encapsulate dry powder compare placebo administer oral inhalation use dry powder inhaler healthy adult . Primary study outcome measure safety tolerability single-dose DAS181 treatment 0.5 mg , 1.0 mg , 2.25 mg , 4.5 mg , measure follow parameter : adverse event , physical exam , vital sign , hematology , clinical chemistry , blood coagulation , complement activation , haptoglobin immunogenicity , urinalysis , throat swab bacterial culture , ECG , chest X-ray , spirometric lung function . Secondary outcome measure systemic exposure pharmacokinetic parameter DAS181 . This phase 1 study double-blind , randomize , placebo-controlled , single-dose escalation study conduct Comprehensive Phase One Miramar campus . Thirty-six 60 healthy male female volunteer , 18-65 year ( inclusive ) , enrol 4 separate step . Each enrollment recruit 9 subject one 4 dose group . Within dose group , participant randomly assign placebo DAS181 , 1:2 ratio . The subject receive single-dose treatment placebo ( 10.5 mg lactose ) , DAS181 one 4 dos : 0.5 mg , 1.0 mg , 2.25 mg , 4.5 mg . The subject screen enrol within 28 day prior dose study drug . The study initiate 0.5 mg dose . Escalation next dose contingent upon meet dose escalation criterion study day 7 post dose follow-up visit ( Visit 4 ) . The day dose always define Day 0 ( study day 0 ) , regardless step cohort . All future visit time period reference day dose . Administration DAS181 placebo give supervision study staff . Subjects enter inpatient clinic day -1 , even prior dosing . Subjects remain inpatient clinic 24 hour post exposure observe sign adverse event ( AEs ) . After 24-hour inpatient observation period , participant discharge deem healthy point . All subject must come back follow-up visit follow study day : 2 , 7 , 14 ( ±1 day ) , 30 ( ±2 day ) .</detailed_description>
	<criteria>Healthy , nonsmoking adult male female volunteer age 18 65 ( inclusive )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Influenza , Flu , DAS181 , Fludase</keyword>
</DOC>